Article

Biological mitral valve prosthesis in a patient supported with a permanent left ventricle assist device.

Deutsches Herzzentrum German Berlin, Germany.
ASAIO journal (American Society for Artificial Internal Organs: 1992) (Impact Factor: 1.39). 09/2011; 57(6):550-2. DOI: 10.1097/MAT.0b013e31822b3e17
Source: PubMed

ABSTRACT Mitral valve pathology, especially status postvalve replacement (biological or mechanical), remains challenging in patients suffering from end-stage heart failure and undergoing left ventricular assist device (LVAD) placement due to several factors (potential source for thromboembolic complications, risk for structural deterioration of the biological prosthesis leading to stenosis, and inadequate LVAD preload). We report a case of long-term LVAD support in a patient with a previously implanted biological mitral valve prosthesis. During LVAD insertion, the valve was left in place, and it functioned well until the death of the patient 3 years later. The patient remained free of any valve-related complications.

0 Bookmarks
 · 
91 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two patients with new mitral valve bioprostheses required implantation of Bio-Medicus centrifugal pumps (Bio-Medicus, Minneapolis, MN) for circulatory support and had evidence of prosthetic valve thrombosis 1 and 4 days later. Both patients died of thromboembolic complications despite surgical removal of the thrombus. Thrombosis is a rare early complication of bioprosthetic valves and in these cases was probably related to low transvalvular flow due to the use of circulatory assist devices. We discuss possible strategies for avoiding and managing this catastrophic complication.
    The Annals of Thoracic Surgery 01/1996; 60(6):1814-6. · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Continuous-flow left ventricular assist devices (LVAD) have emerged as the standard of care for advanced heart failure patients requiring long-term mechanical circulatory support. Evidence-based clinical management of LVAD-supported patients is becoming increasingly important for optimizing outcomes. In this state-of-art review, we propose key elements in managing patients supported with the new continuous-flow LVADs. Although most of the presented information is largely based on investigator experience during the 1,300-patient HeartMate II clinical trial, many of the discussed principles can be applied to other emerging devices as well. Patient selection, pre-operative preparation, and the timing of LVAD implant are some of the most important elements critical to successful circulatory support and are principles universal to all devices. In addition, proper nutrition management and avoidance of infectious complications can significantly affect morbidity and mortality during LVAD support. Optimizing intraoperative and peri-operative care, and the monitoring and treatment of other organ system dysfunction as it relates to LVAD support, are discussed. A multidisciplinary heart failure team must be organized and charged with providing comprehensive care from initial referral until support is terminated. Preparing for hospital discharge requires detailed education for the patient and family or friends, with provisions for emergencies and routine care. Implantation techniques, troubleshooting device problems, and algorithms for outpatient management, including the diagnosis and treatment of related problems associated with the HeartMate II, are discussed as an example of a specific continuous-flow LVAD. Ongoing trials with other continuous-flow devices may produce additional information in the future for improving clinical management of patients with these devices.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 02/2010; 29(4 Suppl):S1-39. · 3.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The third annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) provides documentation of the current landscape of durable mechanical circulatory support in the United States. With nearly 3,000 patients entered into the database, the transition to continuous-flow pump technology is evident and dramatic. This report focuses on the rapidly expanding experience with mechanical circulatory support as destination therapy. The current 1-year survival of 75% with continuous-flow destination therapy provides a benchmark for the evolving application of this therapy.
    The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 02/2011; 30(2):115-23. · 3.54 Impact Factor